NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2071210039

Registered date:30/06/2021

OP-2024-001 Study

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedParkinson's disease
Date of first enrollment20/07/2021
Target sample size12
Countries of recruitment
Study typeInterventional
Intervention(s)Oral administration of OP-2024 (1 capsule) or control (1 tablet).

Outcome(s)

Primary OutcomePharmacokinetics
Secondary OutcomeSafety

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 40age old
GenderMale
Include criteria1) Healthy Japanese male. 2) Those with age >= 20 to <= 40 years. 3) Those with BMI >= 18.5 to < 25.0. 4) Those who have provided voluntary written consent to participate in the study.
Exclude criteria1) Those with a history of allergies to investigational drug ingredients, drugs, or foods 2) Those who are undergoing treatment for, or have a history of, respiratory, circulatory, central nervous system, gastrointestinal, hepatic, renal, hematopoietic, or endocrine disorders that affect pharmacokinetics 3) Other protocol defined exclusion criteria could apply

Related Information

Contact

Public contact
Name Customer Consulation Room
Address 36F St.Luke&#039;s Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan Tokyo Japan 104-6591
Telephone +81-120-419-363
E-mail chiken@ohara-ch.co.jp
Affiliation OHARA Pharmaceutical Co.,Ltd.
Scientific contact
Name Fumi Taguchi
Address 36F St.Luke&#039;s Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan Tokyo Japan 104-6591
Telephone +81-120-419-363
E-mail chiken@ohara-ch.co.jp
Affiliation OHARA Pharmaceutical Co.,Ltd.